Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Tozasertib + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Tozasertib||MK-0457|VX-680||AURK Inhibitor (Pan) 12 BCR-ABL Inhibitor 28||Tozasertib (VX-680) is a pan-AURK inhibitor with increased potency against Aurora kinase A (AURKA), and has additional activity against BCR-ABL, potentially resulting in decreased tumor growth (PMID: 14981513, PMID: 22772060, PMID: 32017040).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119|Venclyxto||BCL2 inhibitor 25||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|